OptimizeRx Co. (NASDAQ:OPRX) – Equities research analysts at B. Riley issued their Q2 2020 EPS estimates for OptimizeRx in a research note issued on Wednesday, November 6th. B. Riley analyst A. D’silva anticipates that the company will earn $0.06 per share for the quarter. B. Riley has a “Buy” rating and a $21.00 price objective on the stock. B. Riley also issued estimates for OptimizeRx’s Q3 2020 earnings at $0.05 EPS and Q4 2020 earnings at $0.09 EPS.
OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.15). OptimizeRx had a negative return on equity of 4.19% and a negative net margin of 5.32%. The firm had revenue of $5.00 million for the quarter, compared to analyst estimates of $7.21 million.
Shares of OptimizeRx stock opened at $10.13 on Friday. OptimizeRx has a fifty-two week low of $8.92 and a fifty-two week high of $17.24. The firm has a market cap of $170.46 million, a price-to-earnings ratio of 202.60, a price-to-earnings-growth ratio of 1.50 and a beta of 0.42. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.01. The business has a fifty day simple moving average of $13.49 and a 200-day simple moving average of $14.42.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Wells Fargo & Company MN increased its position in OptimizeRx by 9.5% during the second quarter. Wells Fargo & Company MN now owns 13,562 shares of the company’s stock worth $219,000 after buying an additional 1,180 shares during the last quarter. 1492 Capital Management LLC grew its position in shares of OptimizeRx by 118.8% in the second quarter. 1492 Capital Management LLC now owns 265,185 shares of the company’s stock valued at $4,296,000 after purchasing an additional 144,006 shares during the last quarter. Calamos Advisors LLC grew its position in shares of OptimizeRx by 17.0% in the third quarter. Calamos Advisors LLC now owns 312,764 shares of the company’s stock valued at $4,529,000 after purchasing an additional 45,548 shares during the last quarter. Renaissance Technologies LLC acquired a new position in shares of OptimizeRx in the second quarter valued at approximately $520,000. Finally, BlackRock Inc. grew its position in shares of OptimizeRx by 2,111.6% in the second quarter. BlackRock Inc. now owns 607,292 shares of the company’s stock valued at $9,839,000 after purchasing an additional 579,833 shares during the last quarter. 57.32% of the stock is currently owned by hedge funds and other institutional investors.
In other OptimizeRx news, CEO William J. Febbo purchased 5,000 shares of the stock in a transaction on Wednesday, November 6th. The shares were purchased at an average price of $10.38 per share, with a total value of $51,900.00. 8.40% of the stock is owned by insiders.
OptimizeRx Company Profile
OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care.
Featured Article: Convertible Shares
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.